Innate Lymphoid Cells: New Targets for Cutaneous Squamous Cell Carcinoma Immunotherapy

Marjan Azin; Shadmehr Demehri

doi:10.1016/j.jid.2021.04.003

Innate Lymphoid Cells: New Targets for Cutaneous Squamous Cell Carcinoma Immunotherapy

J Invest Dermatol. 2021 Oct;141(10):2320-2322. doi: 10.1016/j.jid.2021.04.003.

Authors

Marjan Azin¹, Shadmehr Demehri²

Affiliations

¹ Center for Cancer Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
² Center for Cancer Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: sdemehri1@mgh.harvard.edu.

PMID: 34560914
DOI: 10.1016/j.jid.2021.04.003

Abstract

The importance of innate immune cells in cancer promotion has been long recognized. Luci et al. (2021) show a key role for innate lymphoid cells (ILCs) in controlling precancerous skin lesions and impaired function of NK cells and ILC1s during progression to cutaneous squamous cell carcinoma (cSCC). These results, together with other findings, suggest that activation of ILCs could serve as a novel immunotherapeutic strategy against cSCC.

Publication types

Comment

MeSH terms

Carcinoma, Squamous Cell* / therapy
Humans
Immunity, Innate
Immunotherapy
Killer Cells, Natural
Lymphocytes
Skin Neoplasms* / therapy